Trial of Ultrasound guided carpal tunnel release versus Traditional Open Release (TUTOR)

Kyle R. Eberlin  
*Massachusetts General Hospital*

Christopher J. Dy  
*Washington University School of Medicine in St. Louis*

Mark D. Fischer  
*Twin Cities Orthopedics*

James L. Gluck  
*Kansas Orthopaedic Center*

F. Thomas D. Kaplan  
*Indiana Hand to Shoulder*

*See next page for additional authors*

Follow this and additional works at: https://digitalcommons.wustl.edu/oa_4

**Recommended Citation**

Eberlin, Kyle R.; Dy, Christopher J.; Fischer, Mark D.; Gluck, James L.; Kaplan, F. Thomas D.; McDonald, Thomas J.; Miller, Larry E.; Palmer, Alexander; Walker, Marc E.; and Watt, James F., "Trial of Ultrasound guided carpal tunnel release versus Traditional Open Release (TUTOR)." Medicine. 101, 41. e30775 (2022).

https://digitalcommons.wustl.edu/oa_4/674
1. Introduction

Carpal tunnel syndrome (CTS) is the most common peripheral compression neuropathy, affecting approximately 5% of the population. A multitude of treatments are available to treat CTS including activity modification, bracing/splinting, hand therapy, modalities (e.g., therapeutic lasers or ultrasound, iontophoresis), acupuncture, corticosteroid injections, and carpal tunnel release (CTR) surgery. Currently, there is no universally accepted algorithm to guide treatment for patients suffering from CTS. The American Academy of Orthopedic Surgey CTS Clinical Practice Guidelines reported that only 3 treatments are strongly supported in the literature: splinting, corticosteroid injections, and CTR. Although some patients...
with mild to moderate symptoms are successfully treated with splinting and/or corticosteroid injections, those with progressive, refractory, or severe symptoms often undergo CTR for definitive management.\[1,4-5] The goal of CTR is to reduce pressure on the median nerve by dividing the transverse carpal ligament (TCL) while avoiding iatrogenic injury to surrounding neurovascular structures. Among approximately 600,000 CTR procedures performed in the United States annually\[1,10] most (70%-80%) use an open technique (OCTR) during which a palmar incision is made to dissect down to the TCL and transect it using a scalpel, scissors, or a similar cutting device.\[11-13] The standard OCTR technique requires a relatively large incision of 3 to 5 cm and may be associated with a prolonged recovery period due to palmar pain and the need to protect the wound.\[12,14-17]

Over time, there has been a trend to use smaller incisions (1-3 cm) to reduce surgical morbidity using mini-OCTR (mOCTR) or endoscopic CTR.\[15,16-18] Because long-term outcomes and complication profiles are generally equivalent among these CTR procedures,\[15] factors related to patient recovery time such as time to return to normal activities and work absenteeism are important considerations that may assist in shared treatment decision-making between physicians and patients.

In recent years, multiple studies have demonstrated the feasibility of using ultrasound to perform CTR through even smaller incisions while maintaining or improving visualization of the carpal tunnel region, including its at-risk neurovascular structures. During CTR using ultrasound guidance (CTR-US), the carpal tunnel is typically accessed through a single small wrist or palmar incision less than 5 mm length and the TCL is transected using a small knife or similar cutting instrument while the carpal tunnel structures are monitored using ultrasound during the procedure. To date, 13 clinical studies have been published reporting results on over 1300 hands in over 1000 patients at up to 2 years post-treatment comparing recovery time, effectiveness, and safety in subjects with CTS treated with CTR-US or mOCTR.\[20-32] Among these over 1300 hands, there were no major neurovascular complications, and the clinical success rate was over 95%. Furthermore, 2 randomized controlled trials and 1 prospective non-randomized trial demonstrated superior early outcomes for CTR-US compared to mOCTR.\[22,23,29] However, these trials have been limited by small sample size, short follow-up duration, or both. No randomized controlled trial comparing CTR-US to mOCTR has been performed with a sample size over 100 patients and with at least 1 year of follow-up. Thus, the objective of this randomized controlled trial is to compare the safety and effectiveness of CTR-US versus mOCTR in a large cohort of subjects (n = 120) with symptomatic CTS followed for 1 year post-treatment.

### 2. Design and Methods

This paper describes the rationale and design of TUTOR (Trial of Ultrasound guided CTR versus Traditional Open Release). The protocol was developed in accordance with the SPIRIT 2013 guidance for protocols of clinical trials.\[33]

#### 2.1. Study design

This is a prospective, multicenter, randomized controlled trial that will be performed at up to 12 sites in the United States. Subject recruitment in the study began July 26, 2022. A total of 120 subjects will be enrolled and randomized (2:1) to receive CTR-US or mOCTR. The total study duration is expected to be approximately 1.5 years, with 6 months of anticipated subject recruitment and 1 year of follow-up. The trial was prospectively registered at ClinicalTrials.gov (NCT05405218) before first subject enrollment. The trial was funded by Sonex Health, Inc. (Eagan, MN) who was involved in trial design, but will not be involved in data analysis or publication of trial results. Ongoing trial oversight will be provided by a data safety monitoring board (DSMB) and data will be routinely monitored for accuracy. A list of investigational sites and trial oversight committees is provided in Table 1.

#### 2.2. Participants and eligibility criteria

Study participants will undergo a preoperative clinical examination and diagnostic ultrasound of the median nerve. Key eligibility criteria of the trial are a clinical diagnosis of unilateral or bilateral idiopathic CTS, a score of 12 or greater on the CTS-6 questionnaire in the target hand,\[4\] median nerve cross-sectional area ≥10 mm² in the proximal carpal tunnel region of the target hand,\[4\] absence of carpal tunnel symptoms in the contralateral hand that interfere with work or daily activities, and prior failure of nonsurgical CTS treatment. Key exclusion criteria are previous surgery on the target hand or wrist, recent (<6 weeks) corticosteroid injection in the target hand or wrist, need for additional operative procedure, and planned surgical or interventional procedure on the contralateral wrist or hand. Subjects

### Table 1

| Name                      | Institution                        | Location            |
|---------------------------|------------------------------------|---------------------|
| Kyle R. Eberlin, MD **    | Massachusetts General Hospital      | Boston, MA          |
| Christopher J. Dy, MD, MPH, FACS | Washington University            | St. Louis, MO       |
| James F. Watt, MD         | Orthopedic Associates               | Fort Walton, FL     |
| James L. Gluck, MD        | Kansas Orthopaedic Center          | Wichita, KS         |
| Alexander Palmer, DO      | Sano Orthopedics                   | Lee’s Summit, MO    |
| F. Thomas D. Kaplan, MD, FAAS | Indiana Hand to Shoulder          | Indianapolis, IN    |
| Thomas J. McDonald, MD    | Sierra Orthopedic Institute        | Sonora, CA          |
| Mark D. Fischer, MD       | Twin Cities Orthopedics            | Maple Grove, MN     |
| Marc E. Walker, MD, MBA   | University of Mississippi Medical Center | Jackson, MS         |

**Site investigators**

**Data safety monitoring board**

**Independent medical reviewer**

**Site investigators**

**Data safety monitoring board**

**Independent medical reviewer**

**TUTOR = Trial of Ultrasound guided carpal tunnel release versus Traditional Open Release**

**Up to 12 investigational sites may participate in this study. The list of sites in the table represents those that were active as of September 12, 2022.**

**Study principal investigator.**
who meet all preoperative eligibility criteria will be randomized to receive CTR-US or mOCTR. A complete list of study eligibility criteria is provided in Table 2.

2.3. Randomization

The randomization sequence for this trial was developed by an independent biostatistician and computer-generated by an electronic data capture system (Viedoc, Philadelphia, PA). A 2:1 (CTR-US: mOCTR) randomization ratio will be utilized with the randomization sequence stratified by site using variable block sizes to minimize treatment allocation predictability. Treatment assignment will be concealed until it is presented to authorized site personnel at the time of randomization.

2.4. Blinding

Because of obvious differences in surgical technique, it is not possible to blind the treating physicians. As the result of notable visual differences in the postoperative scar between surgical techniques (~3–5 mm for CTR-US and ~1–3 mm for mOCTR), it is not possible to blind the subjects. Due to the fact that the majority of data collected in this trial will be subject-reported, it is not feasible to blind outcome assessors (i.e., subjects).

2.5. Surgical procedure

Subjects randomized to CTR-US will be treated with the commercially available UltraGuideCTR (Sonex Health, Inc., Eagan, MN). The device is a single-use, hand-held device that is inserted into the carpal tunnel through a small (typically <5 mm) incision at the proximal wrist using real-time ultrasound guidance. The working tip of the UltraGuideCTR consists of 2 inflatable balloons that border a centrally located, retractive retrograde cutting blade. Ultrasound is used to position the tip inferior and distal to the TCL and the balloons are inflated with sterile saline, increasing the tip diameter to 8 mm. The inflated balloons displace the median nerve and ulnar artery away from the device, with safe position verified with ultrasound. The blade is then activated, and the TCL is transected in a retrograde manner, with ultrasound visualizing the transection and verifying safe position of the neurovascular structures. Following TCL transection, the blade is resected, the balloons are deflated, and the device is removed. The TCL is then probed to ensure a complete release. In subjects randomized to mOCTR, the TCL will be divided through a 1 to 3 cm incision in standard fashion without ultrasound guidance. Postoperative patient care instructions will be standardized for each treatment group and among all participating sites in order to minimize bias. Investigators will instruct subjects to participate in activities and return to work, as tolerated, based on pain, function, and wound healing status.

2.6. Outcomes

Subject data will be recorded using electronic case report forms and will be routinely monitored for accuracy. Follow-up assessments will occur daily for the first 14 post-procedure days, and at 4 weeks, 3 months, 6 months, and 1 year post-treatment thereafter. Time to return to normal activities and return to work will be assessed daily. Boston Carpal Tunnel Questionnaire Symptom Severity Scale (BCTQ-SSS) and Functional Status Scale (BCTQ-FSS), Numeric Pain Scale, EuroQoL-5 Dimension 5-Level (EQ-5D-5L), and adverse events (AEs) will be assessed at each follow-up interval. A schedule of subject assessments during the study is provided in Table 3.

Table 2

Subject eligibility criteria.

| Inclusion Criteria | Exclusion Criteria |
|--------------------|-------------------|
| 1. ≥18 yrs of age | 1. Prior surgery on the target wrist or hand with the exception of trigger finger that has clinically recovered |
| 2. Clinical diagnosis of unilateral or bilateral idiopathic CTS | 2. History of prior surgical CTR in the target hand |
| 3. CTS-6 score >12 in target hand | 3. History of prior surgical CTR in the contralateral hand within 3 mo of enrollment or with persistent symptoms that interfere with normal daily activities or work at the time of consent |
| 4. Absence of carpal tunnel symptoms in the contralateral hand that interfere with normal daily activities or work at the time of consent and are not anticipated to interfere with return to activities or return to work within 3 mo post-operatively | 4. Corticosteroid injection in the target wrist or hand within 6 wks of randomization |
| 5. Median nerve cross-sectional area ≥10 mm² in the proximal carpal tunnel region of the target hand measured by diagnostic ultrasound | 5. Presence of additional process in the target wrist or hand requiring additional intervention beyond carpal tunnel release (e.g., neurolysis, mass removal, tenosynovectomy) |
| 6. Prior failure of one or more nonsurgical treatment options for the target hand (e.g., physical activity modification, bracing, splinting, corticosteroid injection) | 6. Clinically significant degenerative arthritis of the upper limb (shoulder to hand) on the target side |
| 7. Subject agrees to complete follow-up questionnaires over a 12-mo period | 7. Clinically significant inflammatory disease (including tenosynovitis) of the upper limb (shoulder to hand) on the target side |
| 8. Subject has a valid mobile phone number and email address to receive and answer follow-up questionnaires | 8. Clinically significant trauma or deformity of the upper limb (shoulder to hand) on the target side |
| 9. Median nerve cross-sectional area ≥10 mm² in the proximal carpal tunnel region of the target hand measured by diagnostic ultrasound | 9. Clinically significant vascular disease (including Raynaud’s phenomenon) of the upper limb (shoulder to hand) on the target side |
| 10. Clinically significant neurological disorder (including complex regional pain syndrome) of the upper limb (shoulder to hand) on the target side | 10. Clinically significant periarticular deformities of the upper limb (shoulder to hand) on the target side |
| 11. Planned surgical or interventional procedure on the contralateral wrist or hand | 11. Planned surgical or interventional procedure on the contralateral wrist or hand |
| 12. Systemic inflammatory disease (e.g., rheumatoid arthritis, lupus) | 12. Systemic inflammatory disease (e.g., rheumatoid arthritis, lupus) |
| 13. Amyloidosis | 13. Amyloidosis |
| 14. Chronic renal insufficiency requiring dialysis | 14. Chronic renal insufficiency requiring dialysis |
| 15. Diabetes not controlled by a stable dose of medication over the past 3 mo | 15. Diabetes not controlled by a stable dose of medication over the past 3 mo |
| 16. Uncontrolled thyroid disease | 16. Uncontrolled thyroid disease |
| 17. Pregnant or planning pregnancy in the next 12 mo | 17. Pregnant or planning pregnancy in the next 12 mo |
| 18. Workers compensation subjects | 18. Workers compensation subjects |
| 19. Inability to provide a legally acceptable Informed Consent Form and/or comply with all follow-up requirements | 19. Inability to provide a legally acceptable Informed Consent Form and/or comply with all follow-up requirements |
| 20. Subject has other medical, social or psychological conditions that, in the opinion of the investigator, preclude them from receiving the pretreatment, required treatment, and post-treatment procedures and evaluations | 20. Subject has other medical, social or psychological conditions that, in the opinion of the investigator, preclude them from receiving the pretreatment, required treatment, and post-treatment procedures and evaluations |
Study assessments at each follow-up interval.

| Assessment                        | Baseline | Procedure | Post-Op | Daily 1-14 | 1 mo | 3 mo | 6 mo | 12 mo |
|-----------------------------------|----------|-----------|---------|------------|------|------|------|-------|
| Demographics                      | ✔️       | ✔️        |         |            |      |      |      | ✔️    |
| Ultrasound median nerve CS measurement | ✔️        | ✔️       | ✔️      | ✔️         | ✔️  |      |      | ✔️    |
| CTS-6                             | ✔️       | ✔️        | ✔️      | ✔️         | ✔️  |      |      | ✔️    |
| Randomization                     | ✔️       | ✔️        | ✔️      | ✔️         | ✔️  |      |      | ✔️    |
| Procedure                         | ✔️       | ✔️        | ✔️      | ✔️         | ✔️  |      |      | ✔️    |
| Image of incision                 | ✔️       | ✔️        | ✔️      | ✔️         | ✔️  |      |      | ✔️    |
| Subject-reported Outcomes         |          |           |         |            | ✔️  | ✔️  | ✔️  | ✔️    |
| Demographics                      | ✔️       | ✔️        | ✔️      | ✔️         | ✔️  |      |      | ✔️    |
| Medical history                   | ✔️       | ✔️        | ✔️      | ✔️         | ✔️  |      |      | ✔️    |
| BCTQ-SSS                          | ✔️       | ✔️        | ✔️      | ✔️         | ✔️  |      |      | ✔️    |
| BCTQ-FSS                          | ✔️       | ✔️        | ✔️      | ✔️         | ✔️  |      |      | ✔️    |
| EQ-5D-5L                          | ✔️       | ✔️        | ✔️      | ✔️         | ✔️  |      |      | ✔️    |
| Numeric Pain Scale                | ✔️       | ✔️        | ✔️      | ✔️         | ✔️  |      |      | ✔️    |
| Procedure                         | ✔️       | ✔️        | ✔️      | ✔️         | ✔️  |      |      | ✔️    |
| Images of wound healing           | ✔️       | ✔️        | ✔️      | ✔️         | ✔️  |      |      | ✔️    |
| Return to activities              | ✔️       | ✔️        | ✔️      | ✔️         | ✔️  |      |      | ✔️    |
| Return to work                    | ✔️       | ✔️        | ✔️      | ✔️         | ✔️  |      |      | ✔️    |
| Pain medication                   | ✔️       | ✔️        | ✔️      | ✔️         | ✔️  |      |      | ✔️    |

* Collected at 14-day evaluation only.
** Collected at 7-day and 14-day evaluation only.

BCTQ-FSS = Boston Carpal Tunnel Questionnaire Functional Status Scale, BCTQ-SSS = Boston Carpal Tunnel Questionnaire Symptom Severity Scale; EQ-5D-5L, EuroQoL-5 Dimension 5-Level.

The primary endpoint of the study is the percentage of patients who return to normal daily activities within 3 days of the procedure. Secondary endpoints of the study are median time to return to normal daily activities, percentage of patients who return to work within 3 days of the procedure, median time to return to work, BCTQ-SSS change score at 3 months, BCTQ-FSS change score at 3 months, Numeric Pain Scale change score at 3 months, EQ-5D-5L change score at 3 months, and the incidence of device- or procedure-related AEs at 3 months. The 3-month follow-up interval was selected for analysis of secondary endpoints because the majority of clinical improvement after CTR occurs in the first 3 months, with marginal improvement thereafter.[35,36]

Among study subjects who report full-time or part-time employment preoperatively, time to return to work is defined as the number of days between treatment and the time the subject reports returning to work in any capacity. The BCTQ is a CTS-specific questionnaire that is highly reproducible, internally consistent, valid, and responsive to clinical change in CTS and subject status post-CTR.[37] The BCTQ consists of 11 symptom severity questions (BCTQ-SSS) that are scored from 1 to 5, with higher scores indicating more severe symptoms, and is calculated as the mean of each response. The BCTQ additionally consists of 8 functional status questions that are scored from 1 to 5, with higher scores indicating more functional limitation, and is calculated as the mean of each response. Subjects will be asked to rate their wrist pain severity on a Numeric Pain Scale ranging from 0 to 10, where 0 represents “no pain” and 10 represents “the worst pain imaginable.” The EQ-5D-5L is a generic preference-based questionnaire that measures quality of life across 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is scored on a 5-level severity ranking consisting of: no problems, slight problems, moderate problems, severe problems, unable to/extreme problems.[38]

Subject safety will be assessed by recording AEs. An AE is defined as any adverse change (i.e., de novo or preexisting condition) from the subject’s baseline medical condition occurring after the initial procedural incision has been initiated. Determination of whether a subject experienced an AE can be made in 3 different ways. First, an AE can be documented by the site during the study procedure. Second, a subject may report a postoperative AE directly via phone call to the investigative site. Third, an AE can be identified by the site during the review of the subject-uploaded wound healing images. If the site identifies a potential AE based on image review or is notified of a potential AE by the subject, confirmation of the AE will occur by a phone call with the subject or, if necessary, by asking the subject to return for a follow-up clinical evaluation.

Adverse events will be classified by seriousness and relationship to the device or procedure. A serious adverse event is defined as one that suggests a significant hazard or side effect, regardless of the relationship to the device or procedure. This includes, but may not be limited to, any event that results in death; is life threatening or places the participant at immediate risk of death from the event as it occurred; requires or prolongs hospitalization; causes persistent or significant disability or incapacity; results in congenital anomalies or birth defects; or is another condition which investigators judge to represent significant hazards. A device-related AE is directly attributable to the device or to improper use of the device. A procedure-related AE is directly attributable to the procedure, irrespective of the device, including complications from anesthesia or other procedures incidental to CTR. The relationship of the AE to the device or procedure will be determined by the site investigator using the following definitions:

- **Definite:** The AE follows a reasonable temporal sequence from the time of the index procedure, which includes AEs that occur during the index procedure or during the follow-up period.
- **Probable:** The AE follows a reasonable temporal sequence from the time of the index procedure, and the possibility can be excluded that factors other than the index procedure, such as underlying disease, concomitant drugs, or concurrent treatment caused the AE.
- **Possible:** The AE follows a reasonable temporal sequence from the time of the index procedure and the possibility of
Enrolled subjects will provide informed consent before study participation. The authors intend to report the results of this trial at medical conferences and peer-reviewed journals.

3. Discussion
CTR is a common surgical procedure that can be performed using standard open, mini-open, limited incision, endoscopic, or ultrasound-guided techniques. The results derived from TUTOR will fill an important research gap because there is currently limited evidence directly comparing the safety and effectiveness of CTR-US and mOCTR. Major strengths of the current trial include generation of Level 1 comparative evidence, a large sample size derived from multiple investigative sites, long-term follow-up, and rigorous study oversight by an independent medical reviewer and a DSMB. The initial 3-month results of this trial, including assessment of the return to normal daily activities primary endpoint, are planned to be reported in mid-2023. The outcomes of TUTOR will have important clinical and economic implications for all stakeholders involved in treating patients with CTS.

Acknowledgments
The authors had no writing assistance in the preparation of this manuscript.

Author contributions
Investigation: Kyle R. Eberlin, Christopher J. Dy, Mark D. Fischer, James L. Gluck, F. Thomas D. Kaplan, Thomas J. McDonald, Larry E. Miller, Alexander Palmer, Marc E. Walker, James F. Watt.
Methodology: Kyle R. Eberlin, Christopher J. Dy, Mark D. Fischer, James L. Gluck, F. Thomas D. Kaplan, Thomas J. McDonald, Larry E. Miller, Alexander Palmer, Marc E. Walker, James F. Watt.
Writing – review & editing: Kyle R. Eberlin, Christopher J. Dy, Mark D. Fischer, James L. Gluck, F. Thomas D. Kaplan, Thomas J. McDonald, Larry E. Miller, Alexander Palmer, Marc E. Walker, James F. Watt.

References
[1] Atroshi I, Gummesson C, Johnsson R, et al. Prevalence of carpal tunnel syndrome in a general population. Jama. 1999;282:153–8.
[2] Chammas M. Carpal tunnel syndrome. Chir Main. 2014;33:75–94.
[3] Padua L, Coraci D, Erra C, et al. Carpal tunnel syndrome: clinical features, diagnosis, and management. Lancet Neurol. 2016;15:1273–84.
[4] Graham B, Peljovich AE, Afra R, et al. The American academy of orthopaedic surgeons evidence-based clinical practice guideline on: management of carpal tunnel syndrome. J Bone Joint Surg Am. 2016;98:1750–4.
[5] Tulipan JE, Ilyas AM. Carpal tunnel syndrome surgery: what you should know. Plastic Reconstructive Surg – Global Open. 2020;8:e2692.
[6] Evers S, Bryan AJ, Sanders TL, et al. Corticosteroid injections for carpal tunnel syndrome: long-term follow-up in a population-based cohort. Plast Reconstr Surg. 2017;140:338–47.
[7] Sears ED, Swiatek PR, Chung KC. National utilization patterns of steroid injection and operative intervention for treatment of common hand conditions. J Hand Surg Am. 2016;41:367–373.e2.
[8] Wozahn RD, Foeger NC, Gelberman RH, et al. Long-term outcomes following a single corticosteroid injection for trigger finger. J Bone Joint Surg Am. 2014;96:1849–54.
[9] Mason W, Ryan D, Khan A, et al. Injection versus decompression for carpal tunnel syndrome-pilot trial (INDICATE-P)-protocol for a randomised feasibility study. Pilot Feasibility Stud. 2017;3:20.
[10] Greenfeld PT, Spencer CG, Dawes A, et al. The preoperative cost of carpal tunnel syndrome. J Hand Surg Am. 2022;47:752–61.
[11] Leinberry CF, Rivlin M, Malfentfort M, et al. Treatment of carpal tunnel syndrome by members of the American society for surgery of the hand: a 25-year perspective. J Hand Surg Am. 2012;37:1997–2003.e3.

2.7. Statistical analysis
A sample size of 120 subjects was calculated by assuming the percentage of subjects who would return to normal daily activities within 3 days of the procedure would be 60% in the CTR-US group and 25% in the mOCTR group, 2:1 (CTR-US: mOCTR) randomization ratio, and no more than 15% subject attrition using a Fisher’s exact test with a 2-tailed alpha level of 0.05 and 90% statistical power.

All statistical analyses will be performed by an independent biostatistician. The analysis population of this trial will consist of all randomized subjects who receive their assigned treatment. Baseline data will be analyzed using descriptive statistics. Continuous data will be summarized using mean and standard deviation for normally distributed data, median and interquartile range for non-normally distributed data, and counts and percentages for categorical data. For categorical variables, percentages will be calculated based on non-missing data.

The primary endpoint will be reported as the percentage of patients in each treatment group who return to normal daily activities within 3 days of the procedure. Time to return to normal daily activities and time to return to work among employed individuals will be reported as the median and interquartile range in each treatment group. Due to the likelihood that the data distribution will likely be positively skewed, the nonparametric Mann–Whitney U test will be the statistical test used to assess these endpoints. Differences between the CTR-US and mOCTR groups with respect to longitudinally measured continuous outcomes (i.e., BCTQ-SSS, BCTQ-FSS, Numeric Pain Scale, EQ-5D-5L) will be analyzed using mixed model analysis and adjusting for the baseline score. Adverse events will be reported using counts, percentages and exact 95% confidence intervals using Clopper-Pearson’s method. The incidence of adverse events will be compared using Fisher’s exact test. Statistical analyses will be performed using a 2-sided hypothesis test at a 5% level of significance. No adjustments for multiplicity are planned. Missing data imputation will not be performed.

2.8. Ethics and dissemination
The protocol for this clinical trial was approved by a central institutional review board (WCG IRB, Puyallup, WA) and all enrolled subjects will provide informed consent before study participation. The independent medical reviewer will review AEs for AE classification, seriousness, and relationship to the device or procedure. Discrepancies between the investigational site and the independent medical reviewer will be handled by discussion, with the determination of the independent medical reviewer serving as the final classification.

A DSMB will oversee enrollment and safety of the study subjects, and will advise the study sponsor to continue the trial with no modification, or to modify the trial as appropriate if enrollment or safety concerns are identified. Members of the DSMB will be independent of the sponsor and investigational sites.
[12] Kim PT, Lee HJ, Kim TG, et al. Current approaches for carpal tunnel syndrome. Clin Orthop Surg. 2014;6:253–7.
[13] Fajardo M, Kim SH, Szabo RM. Incidence of carpal tunnel release: trends and implications within the United States ambulatory care setting. J Hand Surg Am. 2012;37:1599–605.
[14] Li Y, Luo W, Wu G, et al. Open versus endoscopic carpal tunnel release: a systematic review and meta-analysis of randomized controlled trials. BMC Musculoskelet Disord. 2020;21:272.
[15] Vasiliadis HS, Nikolakopoulou A, Shrier I, et al. Endoscopic and open versus extended open release for severe carpal tunnel syndrome. Hand (N Y). 2005;30:493–9.
[16] Cellocco P, Rossi C, Bizzarri F, et al. Mini-open blind procedure versus limited open technique for carpal tunnel release: a 30-month follow-up study. J Hand Surg Am. 2005;30:493–9.
[17] Williamson ERC, Vasquez Montes D, Melamed E. Multistate comparison of cost, trends, and complications in open versus endoscopic carpal tunnel release. Hand (N Y). 2021;16:25–31.
[18] Shin EK. Endoscopic versus open carpal tunnel release. Curr Rev Musculoskelet Med. 2019;12:509–14.
[19] Wang PH, Li CL, Shao CJ, et al. Ultrasound-guided percutaneous carpal tunnel release in patients on hemodialysis: early experiences and clinical outcomes. Ther Clin Risk Manag. 2019;15:711–7.
[20] Petrover D, Silvera J, De Baere T, et al. Percutaneous ultrasound-guided carpal tunnel release: study upon clinical efficacy and safety. Cardiovasc Intervent Radiol. 2017;40:758–75.
[21] Rojo-Manaute JM, Capa-Grasa A, Chana-Rodríguez F, et al. Ultrasonographically assisted surgical release of carpal tunnel syndrome: results of a pilot open-label uncontrolled trial conducted outside the operating theatre. Joint Bone Spine. 2015;82:442–5.
[22] Chen TC, Kuo LC, Shao CJ, et al. Ultrasonographically guided percutaneous carpal tunnel release: early clinical experiences and outcomes. Arthroscopy. 2015;31:2400–10.
[23] Capa-Grasa A, Rojo-Manaute JM, Rodriguez FC, et al. Ultra minimally invasive sonographically guided carpal tunnel release: an external pilot study. Orthop Traumatol Surg Res. 2014;100:287–92.
[24] Markison KE. Percutaneous ultrasound-guided MANOS carpal tunnel release technique. Hand. 2013;8:445–9.
[25] Buncke G, McCormack B, Bodor M. Ultrasound-guided carpal tunnel release using the manus CTR system. Microsurgery. 2013;33:362–6.
[26] Nakamichi K, Tachibana S. Ultrasonographically assisted carpal tunnel release. J Hand Surg Am. 1997;22:853–62.
[27] Nakamichi K, Tachibana S, Yamamoto S, et al. Ultrasonographically assisted carpal tunnel release. J Hand Surg Am. 2012;37:353–7.
[28] Fowler JR, Chung KC, Miller LE. Multicenter pragmatic study of carpal tunnel release with ultrasound guidance. Expert Rev Med Devices. 2022;19:273–80.
[29] Chan AW, Tetzlaff JM, Gotzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.
[30] Tran TA, Williams LM, Bui D, et al. Prospective pilot study comparing pre- and postsurgical CTSAQ and Neuro-QoL questionnaire with median nerve high-resolution ultrasound cross-sectional areas. J Hand Surg Am. 2018;43:184 e181–184 e189.
[31] Ozer K, Malay S, Toker S, et al. Minimal clinically important difference of carpal tunnel release in diabetic and nondiabetic patients. Plast Reconstr Surg. 2013;131:1279–85.
[32] Levine DW, Simmons BP, Koris MJ, et al. A self-administered questionnaire for the assessment of severity of symptoms and functional status in carpal tunnel syndrome. J Bone Joint Surg Am. 1993;75:1585–92.
[33] Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727–36.